Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections

Kanao Kobayashi; Satoshi Takahashi; Mitsuru Yasuda; Jun Miyazaki; Koichiro Wada; Masahiro Matsumoto; Hiroshi Hayami; Shingo Yamamoto; Hiroshi Kiyota; Junko Sato; Tetsuya Matsumoto; Naoki Hasegawa; Intetsu Kobayashi; Naoya Masumori; Takahiro Kimura; Hiroki Yamada; Tohru Nakagawa; Tomoyuki Kaneko; Kazumasa Matsumoto; Tetsuya Fujimura; Jun Kamei; Kiyohito Ishikawa; Kiyohide Fujimoto; Yasushi Nakai; Katsumi Shigemura; Takuya Sadahira; Nobuyuki Hinata; Hiroyuki Kitano; Masuo Yamashita; Tomihiko Yasufuku; Hisao Komeda; Yoshiki Hiyama; Yoshito Takahashi; Sojun Kanamaru; Masaya Murakami; Soichi Arakawa; Daisuke Yamada; Koji Mita; Ryoichi Hamasuna; Kazushi Tanaka; Masanori Matsukawa; Eiichiro Takaoka; Masanobu Shigeta; Tadasu Takenaka; Masashi Nishino; Satoshi Ishitoya; Shohei Hayakawa; Kazuhiro Okumura; Masakatsu Ueda

doi:10.1016/j.jiac.2024.03.024

Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections

J Infect Chemother. 2024 Apr 6:S1341-321X(24)00108-9. doi: 10.1016/j.jiac.2024.03.024. Online ahead of print.

Authors

Kanao Kobayashi¹, Satoshi Takahashi², Mitsuru Yasuda², Jun Miyazaki³, Koichiro Wada⁴, Masahiro Matsumoto⁵, Hiroshi Hayami⁶, Shingo Yamamoto⁷, Hiroshi Kiyota⁸, Junko Sato⁹, Tetsuya Matsumoto⁹, Naoki Hasegawa⁹, Intetsu Kobayashi¹⁰, Naoya Masumori¹¹, Takahiro Kimura¹², Hiroki Yamada¹³, Tohru Nakagawa¹⁴, Tomoyuki Kaneko¹⁴, Kazumasa Matsumoto¹⁵, Tetsuya Fujimura¹⁶, Jun Kamei¹⁶, Kiyohito Ishikawa¹⁷, Kiyohide Fujimoto¹⁸, Yasushi Nakai¹⁸, Katsumi Shigemura¹⁹, Takuya Sadahira²⁰, Nobuyuki Hinata²¹, Hiroyuki Kitano²¹, Masuo Yamashita²², Tomihiko Yasufuku²², Hisao Komeda²³, Yoshiki Hiyama²⁴, Yoshito Takahashi²⁵, Sojun Kanamaru²⁶, Masaya Murakami²⁷, Soichi Arakawa²⁸, Daisuke Yamada²⁹, Koji Mita³⁰, Ryoichi Hamasuna³¹, Kazushi Tanaka³², Masanori Matsukawa³³, Eiichiro Takaoka³⁴, Masanobu Shigeta³⁵, Tadasu Takenaka³⁶, Masashi Nishino³⁷, Satoshi Ishitoya³⁸, Shohei Hayakawa³⁹, Kazuhiro Okumura⁴⁰, Masakatsu Ueda⁴⁰

Affiliations

¹ Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Japan Organization of Occupational Health and Safety, Chugoku Rosai Hospital, Hiroshima, Japan. Electronic address: kanaosandy@yahoo.co.jp.
² Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Hokkaido, Japan.
³ Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.
⁴ Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan.
⁵ Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, The University of Occupational and Environmental Health, Fukuoka, Japan.
⁶ Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Hanafusa Urology Clinic(former), Miyazaki, Japan.
⁷ The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Hyogo, Japan.
⁸ The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Iguchi Nephrourology and Internal Medicine Clinic Shinkoiwa, Tokyo, Japan.
⁹ The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
¹⁰ Department of Infection Control and Prevention, Toho University Faculty of Nursing, Tokyo, Japan.
¹¹ Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, Japan.
¹² Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
¹³ Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
¹⁴ Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
¹⁵ Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.
¹⁶ Department of Urology, Jichi Medical University, Tochigi, Japan.
¹⁷ Department of Urology, School of Medicine, Fujita Health University, Aichi, Japan.
¹⁸ Department of Urology, Nara Medical University, Nara, Japan.
¹⁹ Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
²⁰ Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
²¹ Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
²² Department of Urology, Shinko Hospital, Hyogo, Japan.
²³ Department of Urology, Gifu Municipal Hospital, Gifu, Japan.
²⁴ Department of Urology, Hakodate Goryokaku Hospital, Hokkaido, Japan.
²⁵ Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.
²⁶ Department of Urology, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan.
²⁷ Department of Urology, Fuji City General Hospital, Shizuoka, Japan.
²⁸ Department of Urology, Sanda City Hospital, Hyogo, Japan.
²⁹ Department of Urology, Mitoyo General Hospital, Kagawa, Japan.
³⁰ Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital (formerly Hiroshima City Asa Citizens Hospital), Hiroshima, Japan.
³¹ Department of Urology, Shin Kokura Hospital, Fukuoka, Japan.
³² Department of Urology, Kita-Harima Medical Center, Hyogo, Japan.
³³ Department of Urology, Takikawa Municipal Hospital, Hokkaido, Japan.
³⁴ Department of Urology, International University of Health and Welfare Hospital, Tochigi, Japan.
³⁵ Department of Urology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
³⁶ Department of Urology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
³⁷ Department of Urology, Japanese Red Cross Hamamatsu Hospital, Shizuoka, Japan.
³⁸ Department of Urology, Japanese Red Cross Otsu Hospital, Shiga, Japan.
³⁹ Department of Urology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
⁴⁰ Department of Urology, Tenri Hospital, Nara, Japan.

PMID: 38588797
DOI: 10.1016/j.jiac.2024.03.024

Abstract

Introduction: Antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using the national surveillance data, comprising 793 bacterial strains from eight clinically relevant species.

Materials and methods: Data were collected for the fourth national surveillance project from July 2020 to December 2021 by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Disease, and the Japanese Society of Clinical Microbiology. Surveillance was supervised with the cooperation of 43 medical institutions throughout Japan.

Results: Fluoroquinolone required a minimum inhibitory concentration (MIC) of 2-64 mg/L to inhibit the 330 tested Escherichia coli strains. The proportion of levofloxacin-resistant E. coli strains increased from 28.6% in 2008 to 29.6% in 2011, 38.5% in 2015, and 44.5% in 2021. The proportion of levofloxacin-resistant strains of Pseudomonas aeruginosa also increased from previous survey results, showing a continuing downward trend. Conversely, the proportion of levofloxacin-resistant strains of Enterococcus faecalis decreased relative to previous reports. Neither multidrug-resistant P. aeruginosa nor carbapenem-resistant Enterobacteriaceae were detected. For methicillin-resistant Staphylococcus aureus (MRSA), the proportion of vancomycin-susceptible strains (MIC of 2 μg/mL) decreased from 14.7% to 7.7%.

Discussion: Bacterial strains that produced extended-spectrum β-lactamase included E. coli (82/330 strains, 24.8%), Klebsiella pneumoniae (11/68 strains, 16.2%), and Proteus mirabilis (4/26 strains, 15.4%). As compared to previous surveillance reports, these strains showed an increase in proportion over the years.

Keywords: Antimicrobial susceptibility pattern; Complicated urinary tract infection; Minimum inhibitory concentration; Surveillance.

Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.